Dopamine agonists can be used as a first-line treatment for Parkinson's disease.

Dopamine agonists, such as pramipexole and ropinirole, directly stimulate dopamine receptors in the brain to help manage Parkinson’s symptoms. They can be used as first-line therapy, especially in younger patients, to delay the need for levodopa and reduce the risk of long-term motor complications. Their use helps maintain motor function while minimizing early dyskinesias associated with levodopa therapy.